An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and TB-500. The panel rejected emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem's stock remained stable after the vote. A recent study indicated peptides may assist with combating antibiotic-resistant bacteria. Meanwhile, Robert F. Kennedy Jr. pushed for easier access to controversial peptides, calling for slackened rules. The vote reflects a broader shift in how regulators view specialty peptide therapies, which have drawn increasing interest from patients seeking alternatives to standard drugs. Investigators say peptide treatments could change approaches to resistant infections, though concerns about consistency persist. The committee's endorsement of six peptides clears a path for more broad prescribing, even as watchdogs warn of limited evidence. Sector observers note that peptide-focused companies may see greater investor attention following the panel's decision. The rejection of emideltide, meanwhile, highlights the FDA's cautious stance on some peptide candidates.